Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Galera Therapeutics (GRTX) shares

Learn how to easily invest in Galera Therapeutics shares.

Galera Therapeutics is a biotechnology business based in the US. Galera Therapeutics stocks (GRTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $10.09 – a decrease of 15.18% over the previous week. Galera Therapeutics employs 38 staff and has a market cap (total outstanding stock value) of $90.9 million.

How to buy shares in Galera Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Galera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Galera Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Galera Therapeutics's stock price has had significant negative movement.

Its last market close was $2.85, which is 82.03% down on its pre-crash value of $15.86 and 95.79% down on the lowest point reached during the March crash when the stocks fell as low as $5.58.

If you had bought $1,000 worth of Galera Therapeutics stocks at the start of February 2020, those stocks would have been worth $631.34 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $215.75.

Galera Therapeutics stock price (NASDAQ:GRTX)

Use our graph to track the performance of GRTX stocks over time.

Galera Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$2.85
52-week range$1.19 - $12.99
50-day moving average $2.60
200-day moving average $6.50
Wall St. target price$15.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.30

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Galera Therapeutics price performance over time

Historical closes compared with the close of $2.85 from 2022-01-18

1 week (2022-01-12) -15.18%
1 month (2021-12-17) -3.72%
3 months (2021-10-19) 26.67%
6 months (2021-07-19) -68.47%
1 year (2021-01-19) -71.92%
2 years (2020-01-17) -78.76%
3 years (2019-01-15) N/A
5 years (2017-01-15) N/A

Galera Therapeutics financials

Gross profit TTM $0
Return on assets TTM -49.41%
Return on equity TTM -1063.11%
Profit margin 0%
Book value N/A
Market capitalisation $90.9 million

TTM: trailing 12 months

Galera Therapeutics share dividends

We're not expecting Galera Therapeutics to pay a dividend over the next 12 months.

Galera Therapeutics share price volatility

Over the last 12 months, Galera Therapeutics's shares have ranged in value from as little as $1.19 up to $12.99. A popular way to gauge a stock's volatility is its "beta".

GRTX.US volatility(beta: 1.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galera Therapeutics's is 1.9771. This would suggest that Galera Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Galera Therapeutics overview

Galera Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site